57.20

0.77% -0.425

Royalty Pharma Plc (RPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$57.63

Offen:

$57.635

24-Stunden-Volumen:

1.16M

Relative Volume:

0.40

Marktkapitalisierung:

$25.48B

Einnahmen:

$2.44B

Nettoeinkommen (Verlust:

$1.36B

KGV:

29.96

EPS:

1.9093

Netto-Cashflow:

$574.14M

1W Leistung:

-1.76%

1M Leistung:

-9.39%

6M Leistung:

+17.74%

1J Leistung:

+56.71%

1-Tages-Spanne:

$56.96

$57.91

1-Wochen-Bereich:

$56.96

$58.77

52-Wochen-Spanne:

$35.23

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Firmenname

Royalty Pharma Plc

Sektor

Healthcare (1076)

Branche

Biotechnology (594)

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY

Mitarbeiter

100

Twitter

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	57.22	25.92B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	503.87	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	736.35	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	187.98	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	919.08	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.62	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-30	Hochstufung	UBS	Neutral → Buy
2025-09-30	Eingeleitet	Goldman	Buy
2025-05-16	Eingeleitet	Morgan Stanley	Overweight
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Fortgesetzt	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Fortgesetzt	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Alle ansehen

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - theglobeandmail.com

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Form 4 Royalty Pharma Plc For: 1 October - Investing.com India

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock - MarketBeat

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga

Sep 29, 2026

Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD - TradingView

Sep 29, 2026

RPD Forecast — Price Target — Prediction for 2027 - TradingView

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

RPHC5824522 Bond Profile: Coupon and Redemption - TradingView

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Sep 26, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Eastern Progress

Sep 26, 2026

Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat

Sep 26, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026